Antithrombotics
Articles filed under Antithrombotics.
Heparins PowerPoint presentation
PPT discussing chemistry, mechanism of action, classification,pharmacokinetics and clinical uses of heparin.
Warfarin PowerPoint presentation
PPT on Warfarin pharmacotherapy. Discusses mechanism of action, dosing and target INRs, drug and food interactions, and patient counseling.
The coagulation cascade
Coagulation cascade: several resources (videos, animations and tutorials) depicting coagulation factors and pathways.
COGENT trial: no clopidogrel-PPIs interaction
According to the results of the COGENT trial, the combination of the antiplatelet clopidogrel and the PPI omeprazole does not produce clinically relevant cardiovascular interactions.
Antiplatelet agents: mechanisms of action and general overview
This post is an overview on antiplatelet drugs, we will focus on the classification of agents and their mechanism of action. The most relevant facts related to therapeutics will also be discussed here, followed by a video review by K.G. Paul, M.D. A related article explores the pharmacology of thrombolytic agents. Classification of antiplatelet agents
Prasugrel (Effient): mechanism of action, indications and adverse effects
Overview on the mechanism of action, indications, adverse effects profile of prasugrel (Efient in the EU, Effient in the USA). PowerPoint on the TIMI TRITON 38 trial.
Animation on coagulation physiology and the mechanism of action of glycoprotein IIb/IIIa antagonists
Animation on coagulation physiology and mechanism of action of Gp IIb/IIIa inhibitors (abciximab, eptifibatide and tirofiban) and other antiplatelet drugs.
Warfarin dosing: the role of genes
Warfarin dosing: the genes VKORC1, CYP2C9, CYP4F2 are determinants in the dosing of warfarin. Role in clinical practice of pharmacogenomics: genetic testing to guide warfarin therapy.
FDA approves ATryn (recombinant human antithrombin) for the treatment of hereditary antithrombin deficiency
The FDA issued a press release (February 6th, 2009) announcing the approval of the first biological product produced by genetically engineered animals: recombinant human antithrombin. Some excerpts from the press release: The U.S. Food and Drug Administration today issued its first approval for a biological product produced by genetically engineered (GE) animals. The approval is
Genetic variants of cytochrome P-450 linked to decreased response to clopidogrel (Plavix,Iscover and others)
From Physician’s First Watch: Genetic Variants Linked to Decreased Response to Clopidogrel, Increased Cardiovascular Risk Polymorphisms in the gene encoding the cytochrome P-450 2C19 enzyme (CYP2C19) not only confer reduced response to clopidogrel, but also are associated with increased risk for cardiovascular events, according to three studies published online by the New England Journal of
EMEA positive opinion for prasugrel (Efient)
Press release about the positive opinion of the CHMP for the antiplatelet agent Efient (prasugrel): COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SUMMARY OF POSITIVE OPINION for EFIENT International Nonproprietary Name (INN): prasugrel On 18 December 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing